
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Telix enters a commercial distribution agreement with Radius for Telix’s prostate cancer investigational imaging product…
Read moreNews & Views
Telix enters a commercial distribution agreement with Radius for Telix’s prostate cancer investigational imaging product…
Read moreTelix announces an exclusive licence agreement for a novel PET radiotracer originating from the Université catholique de…
Read moreTelix has completed a Phase I clinical trial of TLX591-CDx for prostate cancer imaging in Japan in collaboration with Kanazawa…
Read moreTelix announces collaboration with Kettering Health on PSMA-targeting…
Read moreTelix is delighted to announce the appointment of Michael Didocha as Chief Financial Officer for the Americas…
Read moreTelix is delighted to announce that Samantha McSherry has joined Telix as Director of Commercial Operations for Australia and New…
Read moreTelix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery…
Read moreTelix Pharmaceuticals Limited Announces Half-year Shareholder…
Read moreTelix announces Half-Year Results 2021 and provides shareholder…
Read moreTelix releases details of two ancillary studies under the ProstACT program, including a Phase II study in collaboration with…
Read more